Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study

doi:10.3389/fonc.2020.602553

	Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study
	Wang, Yuan 6; Feng, Lan-lan 5; Ji, Pei-gang 6; Liu, Jing-hui 6; Guo, Shao-chun 6; Zhai, Yu-long 6; Sankey, Eric W.4; Wang, Yue 3; Xue, Yan-rong 1,2; Wang, Na 6
刊名	FRONTIERS IN ONCOLOGY
	2021-02-15
卷号	10 页码:10
关键词	diffuse midline glioma radiotherapy P53 KPS
ISSN号	2234-943X
DOI	10.3389/fonc.2020.602553
英文摘要	Purpose Diffuse midline gliomas (DMG) with H3K27M mutations have been identified as a rare distinctive entity with unique genetic features, varied molecular alterations, and poor prognosis. The current study aimed to evaluate the clinical characteristics and profile of molecular markers on patients with a DMG harboring H3K27M mutations, and explore the impact of this genetic makeup on overall survival. Methods We retrospectively analyzed 43 consecutive patients diagnosed with a DMG harboring H3K27M mutations (age range 3 to 75 years) and treated in a tertiary institution within China between January 2017 to December 2019. Various clinical and molecular factors were evaluated to assess their prognostic value in this unique patient cohort. Results The median overall survival (OS) was 12.83 months. Preoperative Karnofsky Performance Score (KPS) and adjuvant radiotherapy were found to be independent clinical parameters influencing the OS by multivariate analysis (p = 0.027 and p < 0.001 respectively). Whereas extent of tumor resection failed to demonstrate statistical significance. For molecular markers, P53 overexpression was identified as a negative prognostic factor for overall survival by multivariate analysis (p = 0.030). Conclusion Low preoperative KPS, absence of radiotherapy and P53 overexpression were identified as predictors of a dismal overall survival in patients with DMG and H3K27M mutations.
资助项目	National Natural Science Foundation of China[81601100] ; National Natural Science Foundation of China[81772661]
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000623215300001
资助机构	National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China ; National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://210.72.145.45/handle/361003/12142]
专题	中国科学院国家授时中心
通讯作者	Qu, Yan; Gong, Li; Wang, Liang
作者单位	1.Univ Chinese Acad Sci, Sch Optoelect, Beijing, Peoples R China 2.Chinese Acad Sci, Natl Time Serv Ctr, Xian, Peoples R China 3.Fourth Mil Med Univ, Dept Hlth Stat, Xian, Peoples R China 4.Duke Univ Hosp, Dept Neurosurg, Durham, NC USA 5.Fourth Mil Med Univ, Tangdu Hosp, Dept Pathol, Xian, Peoples R China 6.Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China
推荐引用方式 GB/T 7714	Wang, Yuan,Feng, Lan-lan,Ji, Pei-gang,et al. Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study[J]. FRONTIERS IN ONCOLOGY,2021,10:10.
APA	Wang, Yuan.,Feng, Lan-lan.,Ji, Pei-gang.,Liu, Jing-hui.,Guo, Shao-chun.,...&Wang, Liang.(2021).Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.FRONTIERS IN ONCOLOGY,10,10.
MLA	Wang, Yuan,et al."Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study".FRONTIERS IN ONCOLOGY 10(2021):10.